Why the study?
Does statin therapy reduce cardiovascular disease mortality and morbidity in elderly patients for primary prevention?
Does statin therapy reduce cardiovascular disease mortality and morbidity in elderly patients for primary prevention?
This review highlights the need to carefully weigh the risks of polypharmacy against the potential cardiovascular benefits of statin therapy for primary prevention in the elderly.
Answers are grounded in this paper and cite their sources.
Supports individualized statin risk-benefit assessment in elderly primary prevention; leaves open definitive RCT evidence on net benefit.
The elderly population is increasing worldwide, with subjects > 65 years of age constituting the fastest-growing age group. Furthermore, the elderly face the greatest risk and burden of cardiovascular disease mortality and morbidity. Although elderly patients, particularly those older > 75, have not been well represented in randomized clinical trials evaluating lipid-lowering therapy, the available evidence supporting the use of statin therapy in primary prevention in older individuals is derived mainly from subgroup analyses and post-hoc data. On the other hand, elderly patients often have multiple co-morbidities that require a high number of concurrent medications; this may increase the risk for drug-drug interactions, thereby reducing the potential benefits of statin therapy. The aim of this review was to present the relevant literature regarding statin use in the elderly for their primary cardiovascular disease, with the associated risks and benefits of treatment.
No takes yet. Share an insight, caveat, or question.
Climent et al. (2015) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: